DelveInsight's“ Multiple System Atrophy Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Multiple System Atrophy, historical and forecasted ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...

Alterity Therapeutics is a late clinical-stage biotech company focused on developing treatments for serious neurodegenerative ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing ...

Detailed price information for Tiziana Life Sciences Ltd (TLSA-Q) from The Globe and Mail including charting and trades.

Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi’s tolebrutinib for nrSPMS shows need for safe therapy BOSTON, Dec.

GAINESVILLE, Fla., January 20, 2026--neuropacs™ Corp., a leading innovator in AI-driven neurological diagnostics, announced today the successful raise of over $1.0 million in early-stage capital.

PALOMA study is one of the largest longitudinal studies using eye-movement biomarkers in patients with Parkinson’s diseaseNEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--NeuraLight, the leader in ...

Tiziana Life Sciences ( (TLSA) ) has provided an update.

US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.